Innate Pharma Deal History & Licensing Activity
Innate Pharma is a biotech. Over the past three years, Innate Pharma has been involved in 3 licensing and acquisition transactions, with a primary focus on Antibodies (5 deals). The company currently has 2 active clinical trials, primarily in Oncology.
Deals (12mo)
2
Active Trials
2
Top Modality
Antibodies
Focus Area
Oncology
Innate Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Innate Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| lacutamab | Sobi | Antibodies | Phase 2 | collaboration | Aug 10, 2026 |
| Lacutamab | Swedish Orphan Biovitrum AB (Sobi) | Antibodies | Phase 3 | option | Aug 10, 2026 |
Innate Pharma Pipeline Focus
Therapeutic areas and modalities where Innate Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Innate Pharma Clinical Pipeline
Innate Pharma has 2 active clinical trials across 2 development phases.
1
Phase 1
1
Phase 2
See How Your Asset Matches Innate Pharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Hematology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for hematology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Innate Pharma Licensing & Deal Activity
Innate Pharma is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Innate Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Innate Pharma include Oncology (4 deals and trials), Solid Tumors (2 deals and trials), and Hematology (1 deal and trial). In terms of modality, Innate Pharma has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Innate Pharma and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Innate Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.